Melek K. Eryılmaz
Saraykoy Akyokus Street
Saraykoy, 42080, Turkey
Saraykoy, 42080, Turkey
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.
Journal: Journal of clinical medicine
Published: June 24, 2026
Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 14, 2026
Prognostic Impact of the Systemic Immune-Inflammation Index According to Concurrent Chemotherapy Backbone in Stage III Non-Small Cell Lung Cancer.
Journal: Current oncology (Toronto, Ont.)
Published: May 30, 2026
Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.
Journal: Journal of clinical medicine
Published: May 28, 2026
Clinical and Social Determinants of Treatment Adherence in Cancer Patients: The Contributory Role of Hearing Loss.
Journal: Laryngoscope investigative otolaryngology
Published: April 25, 2026
Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index for Survival in Nivolumab-Treated Metastatic Renal Cell Carcinoma.
Journal: Medicina (Kaunas, Lithuania)
Published: March 29, 2026
Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.
Journal: Medicina (Kaunas, Lithuania)
Published: March 22, 2026
Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma.
Journal: Journal of clinical medicine
Published: January 07, 2026
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.
Journal: Medicina (Kaunas, Lithuania)
Published: November 24, 2025
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: November 14, 2025
Diabetes Increases Immunotherapy-Related Toxicity but Not Efficacy in Metastatic Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.
Journal: International journal of cancer
Published: November 08, 2025
Last Updated: 09/26/2026